Results 201 to 210 of about 4,884,310 (310)

PETER: protocol for a randomised controlled trial of the effects of postal and digital invitations and reminders on participation in colorectal cancer screening among young adults. [PDF]

BMJ Open
Klimeck L, Heisser T, Petzold U, Hennig B, Hoffmeister M, Brenner H.   +5 more
europepmc   +1 more source

Modern Management of Asymptomatic Carotid Stenosis: A Meta‐Analysis of CREST‐2, SPACE‐2, and ECST‐2

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Recent randomized trials (CREST‐2, SPACE‐2, and ECST‐2) have compared carotid revascularization (carotid endarterectomy [CEA] or carotid artery stenting [CAS]) plus contemporary medical therapy (CMT) versus CMT alone in asymptomatic carotid stenosis.
Aasim Ali, Waqar Ahmed Cheema, Fiza Nisar, Muhammad Shamoon, Sameen Sarfaraz, Ahmad Butt, Muhammad Abdullah Ali, Armaghana Abdullah, Muhammad Asad Shabbir, Muhammad Talha, Hammad Azam, Aimen Anwaar Pannun, Usama Saleem, Anousha Tanveer, Mukesh Sharma   +14 more
wiley   +1 more source

Optimizing the Endometrial Factor in Recurrent Implantation Failure: From Established Diagnostics to Mechanism-Informed Management. [PDF]

J Clin Med
Zikopoulos A, Moustakli E, Potiris A, Paraschos VS, Katopodi AT, Kathopoulis N, Anagnostaki I, Tsakiridis I, Dagklis T, Kokkosi E, Sarella A, Zikopoulos K, Stavros S.   +12 more
europepmc   +1 more source

Disease Course After Anti‐CD20 Discontinuation in Secondary Progressive Multiple Sclerosis—A Multicenter Long‐Term Longitudinal Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To describe long‐term outcomes after anti‐CD20 discontinuation in selected patients with secondary progressive multiple sclerosis (SPMS) who remained without subsequent disease‐modifying therapy (DMT). Methods We retrospectively analyzed data from four centers in Austria and Switzerland.
Ferdinand Otto, Dariia Kliushnikova, Richard Friedrich Radlberger, Sinan Yasaroglu, Tobias Moser, Andrea Harrer, Kitty Kratzer, Wolfgang Hitzl, Christiane Gradl, Martin Schmidauer, Patrick Roth, Harald Hegen, Peter Wipfler   +12 more
wiley   +1 more source

Current <i>Helicobacter pylori</i> Diagnostics: Established Methods, Resistance Testing, and Emerging Approaches. [PDF]

JGH Open
Tang T, Paz EA, Yu K, Lee KH, Tay CY, Wang J, Marshall BJ, Hu L, Fu W, Yang Z.   +9 more
europepmc   +1 more source

Progressive Parkinsonism in PPP2R5D‐Related Neurodevelopmental Disorder

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT PPP2R5D‐related neurodevelopmental disorder (Houge–Janssens syndrome type 1) is a rare autosomal dominant condition characterized by macrocephaly, intellectual disability, and epilepsy. Progressive parkinsonism is an emerging adult phenotype that neurologists should be aware of since timely genetic diagnosis opens the door to disease‐modifying
Katerina Bernardi, Enrique Gonzalez Saez‐Diez, Joshua Rong, Beril Ay, Shabbir Merchant, Kathryn Yang, Darius Ebrahimi‐Fakhari   +6 more
wiley   +1 more source

Diagnostic Accuracy of Individual and Multimodal Pulp Sensibility Tests Compared With Radiographic Assessment for the Diagnosis of Pulpal Health: A Prospective Diagnostic Accuracy Study. [PDF]

Cureus
Priya NT, Vanapatla A, Puppala C, T N A, Gaddala N, Mohammad N.   +5 more
europepmc   +1 more source

“Low‐Positive” MOG‐IgG Cases Among Adults With a First Event Suggestive of Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine the prevalence and clinical characteristics of patients with “low‐positive” (LP) MOG‐IgG (titres 1:160–1:320) among adults with a first demyelinating event (FDE) suggestive of multiple sclerosis (MS). Methods From the Barcelona CIS inception cohort, we included adult patients with serum collected ≤ 6 months from the FDE.
Javier Villacieros‐Álvarez, Carmen Espejo, Georgina Arrambide, Mireia Castillo, Marta Rodriguez, Helena Ariño, Iker Elosua, Carmen Tur, Angela Vidal‐Jordana, Andreu Vilaseca, Joaquín Castilló, Ingrid Galán, Luciana Midaglia, Carlos Nos, Breogan Rodríguez‐Acevedo, Ana Zabalza, Luca Bollo, Agustín Pappolla, René Carvajal, Neus Mongay‐Ochoa, Jordi Rio, Jaume Sastre‐Garriga, Manuel Comabella, Gesualdina Busiello, Sofia Sceppacuercia, Àlex Rovira, Xavier Montalban, Mar Tintoré, Cristina Auger, Álvaro Cobo‐Calvo   +29 more
wiley   +1 more source

Multicentre Evaluation of Cepheid Xpert^® Research-Use-Only Panel for Molecular Rapid Detection of Gastrointestinal Pathogens. [PDF]

Microorganisms
Dauwalder O, Kehrmann J, Corvec S, Roelens M, Roussel-Gaillard T, Bixio E, Buer J, Baillemont E, Prodel M, Martinaud C, Cento V.   +10 more
europepmc   +1 more source

Anti‐CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non‐Active Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine whether discontinuing anti‐CD20 therapy in people with relapsing‐onset MS aged over 50 is associated with an increased risk of relapse, inflammatory activity, confirmed disability accrual, and serious infection compared with continuing therapy.
Alexia Moukhine, Fabien Rollot, Romain Casey, Nicolas Collongues, Sandra Vukusic, Guillaume Mathey, Anne Laure Dubessy, Jonathan Ciron, Jérôme De Seze, Aurélie Ruet, Pierre Labauge, Arnaud Kwiatkowski, Hélène Zephir, Caroline Papeix, Gilles Defer, Christine Lebrun‐Frenay, David Axel Laplaud, Eric Berger, Eric Thouvenot, Jean Pelletier, Abdullatif Al Khedr, Olivier Casez, Bertrand Bourre, Abir Wahab, Laurent Magy, Jean‐Philippe Camdessanché, Ines Doghri, Solène Moulin, Mariana Sarov Rivière, Karolina Hankiewicz, Amélie Dos Santos, Corinne Pottier, Eric Manchon, Jennifer Aboab, Maia Tchikviladze, Thomas David, Gilles Edan, Emmanuelle Le Page, Laure Michel, Anne Kerbrat, OFSEP Investigators   +40 more
wiley   +1 more source